Riskpilot← Back to searchSign inGet full accessLACRIMALIS AS
ASActiveOrg 929966155Gartnerveien 27, 4016 StavangerMedical specialists activities · NACE 8622Est. 20220 employees
Revenue 2025
NOK 306K
+9% vs 2024
EBITDA margin
-21.8%
+34% vs 2024
Equity ratio
-249.1%
Financial strength
Net profit 2025
NOK -83K
+30% vs 2024
| Revenue | NOK 306K | +9% |
| EBITDA | NOK -67K | +34% |
| Net profit | NOK -83K | +30% |
| Total assets | NOK 101K | +17% |
| Equity | NOK -252K | -49% |
| Employees | 0 | — |
Legal name
LACRIMALIS AS
Org number
929966155
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
30. september 2022
Share capital
NOK 150 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Company purpose
Utredning og behandling av tørre øyne samt alt hva hermed står i forbindelse, herunder kjøp og salg av varer relatert til formålet. Selskapet kan også drive med andre former for medisinske og kirurgiske behandlinger. Selskapet kan delta i andre selskap med lignende formål.
Address
Gartnerveien 27, 4016 Stavanger
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 56 | 301 | 280 | 306 |
| Staff expenses | −0 | −0 | −0 | −0 |
| EBITDA | −29 | −139 | −102 | −67 |
| Depreciation & amort. | −4 | −16 | −17 | −15 |
| EBIT | −33 | −155 | −119 | −82 |
| Net financials | 0 | 0 | 0 | −1 |
| Profit before tax | −33 | −155 | −119 | −83 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −33 | −155 | −119 | −83 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 122 | 123 | 87 | 101 |
| Equity | 104 | −50 | −169 | −252 |
| Long-term debt | 0 | 90 | 160 | 0 |
| Short-term debt | 18 | 84 | 96 | 353 |
| Total debt | 18 | 174 | 256 | 353 |
EBITDA margin
-21.8%
This company
15.8%
Market median
-238% vs market
20222025
Equity ratio
-249.1%
This company
38.2%
Market median
-752% vs market
20222025
Return on equity
-8293200.0%
This company
18.4%
Market median
-45071839% vs market
20222025
Net profit margin
-27.1%
This company
8.1%
Market median
-435% vs market
20222025
Asset turnover
3.02×
This company
1.12×
Market median
+170% vs market
20222025
Debt / equity
1.40×
This company
0.62×
Market median
-126% vs market
20222025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TI Chief Executive Officer | Chief Executive Officer | 2022 |
ES Deputy Member | Deputy Member | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2023 | |
| Company | 33.33% | 33.33% | 2023 | |
| Company | 33.33% | 33.33% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Øyelege Dr. Meike Sporbeck As
LACRIMALIS AS Board members of LACRIMALIS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tor Inge Moe Wathne | Chief Executive Officer | 0 companies |
| Eivind Støle | Deputy Member | 0 companies |
| Meike Sporbeck | Chairman | 0 companies |